Ipsen SA

PAR:IPN

Strong first half: Ipsen said H1 2026 was marked by “excellent financials,” with total sales up 23.5% at constant exchange rates to EUR 2.2 billion and a core operating margin of 38.6%.

Guidance raised: Management upgraded full-year 2026 guidance to sales growth of more than 20% and core operating margin of more than 37%, citing strong momentum across the portfolio.

Pipeline progress: The company highlighted three positive Phase III readouts, including Dysport in both episodic and chronic migraine and IQIRVO in PBC, while also advancing several late-stage assets.

External innovation: Ipsen added two late-stage acquisitions, Kartos’ navtemadlin and Memo’s potravitug, and said it still has more than EUR 2 billion of remaining firepower for external innovation.

Key questions: Investors focused on Somatuline generic timing, Bylvay growth after the biliary atresia setback, the size of the migraine opportunity for Dysport, and the profit impact of recent deals and future migraine investment.